10-K: Sigyn Therapeutics Reports Annual Results for 2024, Highlights Progress in Medical Device Development

Sigyn Therapeutics' 2024 annual report details the company's ongoing development of medical devices for cancer and infectious disease, including its lead candidate, Sigyn TherapyTM, and its efforts to secure additional capital.

Summary

• Sigyn Therapeutics, Inc. is a development-stage company focused on creating therapeutic solutions for unmet needs in global healthcare, particularly in cancer and infectious disease.
• The company's lead product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders.
• The company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.
• The company had no revenues for the years ended December 31, 2024 and 2023.
• Operating expenses increased slightly to $2,519,242 for 2024, primarily due to increases in professional fees and investor relations costs.
• The company reported a net loss before income taxes of $3,340,212 for 2024.
• As of April 11, 2025, there were 1,605,377 shares of common stock outstanding.
• The company has initiated a Regulation D offering to sell up to 750,000 Units at a price of $5,000 per unit with each Unit consisting of one (1) $5,500 principal amount convertible debenture (convertible at Four dollars ($4.00) per share) and a Warrant to purchase 1,250 shares of common stock at $6.00 per share.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company is making progress in developing its therapeutic candidates and has a clear strategic vision, the lack of revenue, significant net losses, and going concern uncertainty weigh heavily on the overall sentiment. The need for additional capital and the presence of material weaknesses in internal control further contribute to a negative outlook.

Positives

• The company has a broad pipeline of therapeutic candidates targeting significant unmet needs in cancer and infectious disease.
• The company has completed pre-clinical studies of Sigyn Therapy, demonstrating its ability to extract pathogens and toxins from blood.
• The company is planning first-in-human clinical studies of Sigyn Therapy.
• The company owns the intellectual property rights to pending royalty-free patents.
• The company has a experienced management team with a track record of developing and commercializing medical devices.

Negatives

• The company is a development-stage company with no revenues.
• The company has a history of net losses and negative cash flows from operations.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations.
• The company's therapeutic candidates are subject to extensive regulatory requirements and may not receive market approval.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and generate revenues.
• The company's therapeutic candidates may not receive market approval from the FDA or other regulatory agencies.
• The company may face competition from other companies developing similar therapies.
• The company's intellectual property may not be adequately protected.
• The company may be subject to product liability claims.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects that its current working capital position, together with its expected future cash flows from operations will be insufficient to fund its operations in the ordinary course of business, anticipated capital expenditures, debt payment requirements and other contractual obligations for at least the next twelve months. The company may need to obtain additional sources of capital in the future to finance any such acquisitions and/or investments.

Management Comments

• Management intends to raise additional funds by way of a public offering or an asset sale transaction.
• Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern.

Industry Context

The company operates in the medical device industry, specifically focusing on extracorporeal blood purification technologies. This field is driven by the need for innovative treatments for cancer and infectious diseases, particularly those not addressed by traditional drug therapies. The company's focus on optimizing drug delivery and reducing toxicity aligns with industry trends and regulatory initiatives like the FDA's Project Optimus.

Comparison to Industry Standards

• The document mentions Fresenius Medical Care and DaVita, Inc. as dominant players in the dialysis industry, suggesting that Sigyn Therapeutics aims to provide value to these companies by extending the lives of ESRD patients.
• The document references Aethlon Medical, Inc., where Sigyn's CEO previously oversaw the development of the Hemopurifier, a device that received FDA Emergency Use Authorization for Ebola treatment, indicating a benchmark for regulatory success in the blood purification space.
• The document mentions Terumo BCT, ExThera Medical Corporation, CytoSorbents, Inc., and Baxter Healthcare Corporation as companies that received FDA Emergency-Use Authorization to treat Covid-19, indicating a benchmark for regulatory success in the blood purification space.

Management Changes

Corporate Governance

Legal Proceedings

• From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business.

Next Steps

• The company plans to submit an Investigational Device Exemption (IDE) to the FDA to support first-in-human feasibility studies of Sigyn Therapy.
• The company intends to raise additional funds by way of a public offering or an asset sale transaction.
• The company plans to take steps to enhance and improve the design of its internal control over financial reporting.

Key Dates

Keywords

Sigyn Therapeutics, Sigyn Therapy, medical devices, cancer, infectious disease, blood purification, extracorporeal, immunotherapy, chemotherapy, FDA, clinical trials, xenotransplantation, sepsis, endotoxemia, Regulation D, convertible debentures